Division of Pharmacoepidemiology and Pharmacoeconomics, Dept of Medicine, Brigham and Women's Hospital, Harvard Medical School, United States
Disclosure information not submitted.
Comparing Healthcare Utilization and Cost in Empagliflozin vs GLP-1RA Initiators with Type 2 Diabetes without Established Cardiovascular Disease
Tuesday, August 27, 20248:30 AM – 8:45 AM CEST
